Characteristics of hepatitis C treatment with pegylated interferons and ribavirin

Annals of Hepatology

Volumn 9, Issue SUPPL. 1, 2010, Pages 61-64

  Jiménez Méndez, Ricardo ^a   Castañeda Hernández, Gilberto ^a  

^a Centro de Investigación y Estudios Avanzados del Instituto   (Mexico)

Author keywords

Hepatitis C; Interferons; Pegylation; Ribavirin; Treatment options

Indexed keywords

ALBINTERFERON ALPHA2B; ALBUMIN; LEVOVIRIN; MACROGOL; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; RIBAVIRIN DERIVATIVE; VIRUS RNA; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TREATMENT FAILURE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; VIRUS LOAD; VIRUS TYPING; DRUG COMBINATION; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 79952110139     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31726-0     Document Type: Article

References (44)

1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957; 147(927): 258-267.
2. Pestka S. The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem 2007; 282(28):20047-20051.
3. Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 2000; 81(Pt 10): 2341-2364.
4. Sen GC. Viruses and interferons. Annu Rev Microbiol 2001; 55: 255-281.
5. Schultz U, Kaspers B, Staeheli P. The interferon system ofnon-mammalian vertebrates. Dev Comp Immunol 2004; 28(5): 499-508.
6. Gale M Jr. Effector genes of interferon action against hepatitis C virus. Hepatology 2003; 37(5): 975-978.
7. Blatt LM, Davis JM, Klein SB, Taylor MW. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res 1996; 16(7): 489-499.
8. Fish EN, Banerjee K, Stebbing N. The role of three domainsin the biological activity of human interferon-alpha. J InterferonRes 1989; 9(1): 97-114.
9. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315(25): 1575-1578.
10. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronichepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321(22): 1501-1506.
11. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995; 332(22): 1457-1462.
12. Carithers RL Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997; 26(3 l. 1): 83S-88S.
13. McHutchison JG, Gordon SC, Schiff ER, et al. Interferonalfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339(21): 1485-1492.
14. Schvarcz R, Ando Y, Sonnerborg A, Weiland O. Combination treatment with interferon alfa-2b and ribavirin forchronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol 1995; 23(Suppl. 2): 17-21.
15. Veronese FM, Harris JM. Introduction and overview of peptide and protein pegylation. Adv Drug Deliv Rev 2002; 54(4): 453-456.
16. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov; 10(21): 1451-1458.
17. Youngster S, Wang YS, Grace M, et al. Structure, biology, and therapeutic implications of pegylated interferon alpha- 2b. Curr Pharm Des 2002; 8(24): 2139-2157.
18. Wang YS, Youngster S, Bausch J, et al. Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry 2000; 39(35): 10634-10640.
19. Grace M, Youngster S, Gitlin G, et al. Structural and biologic characterization of pegylated recombinant IFNalpha2b. J Interferon Cytokine Res 2001; 21(12): 1103-1115.
20. Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branchedpolyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001; 12(2): 195-202.
21. Reddy KR. Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann Pharmacother 2000; 34(7-8): 915-923.
22. Perry CM, Jarvis B. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. Drugs 2001; 61(15): 2263-2288.
23. Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon- alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000; 68(5): 556-567.
24. PEGASYS PDR. 2010. Ref Type: Generic
25. INTRON-A PDR. 2010. Ref Type: Generic
26. PEG-Intron PDR. 2010. Ref Type: Generic
27. ROFERON-A PDR. 2010. Ref Type: Generic
28. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347(13): 975-982.
29. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitisC: a randomised trial. Lancet 2001; 358(9286):958-965.
30. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatmentof hepatitis C infection. N Engl J Med 2009; 361(6):580-593.
31. Ascione A, De LM, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010; 138(1): 116-122.
32. Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferonalpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010; 138(1): 108-115.
33. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007; 46(1): 37-47.
34. http://www.hgsi.com/albinterferon-alfa-2b.html.2010.
35. Nelson DR, Rustgi V, Balan V, et al. Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponderswith chronic hepatitis C. Clin Gastroenterol Hepatol 2009; 7(2): 212-218.
36. Zeuzem S, Yoshida EM, Benhamou Y, et al. Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C. Hepatology 2008; 48(2): 407-417.
37. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35(5): 1002-1009.
38. Foster GR. Past, present, and future hepatitis C treatments. Semin Liver Dis 2004; 24(Suppl.2): 97-104.
39. Shields WW, Pockros PJ. Ribavirin analogs. Clin Liver Dis 2009; 13(3): 419-427.
40. Benhamou Y, Afdhal NH, Nelson DR, et al. A phase III study of the safety and efficacy of viramidine versus ribavirin intreatment-naive patients with chronic hepatitis C: ViSER1results. Hepatology 2009; 50(3): 717-726.
41. Kearney KR, Thornton JJ, Navarro VJ. Taribavirin for the treatment of chronic hepatitis C. Expert Opin Pharmacother 2008; 9(18): 3243-3249.
42. McHutchison JG, Poynard T. Combination therapy with interferonplus ribavirin for the initial treatment of chronichepatitis C. Semin Liver Dis 1999; 19(Suppl. 1): 57-65.
43. Tong MJ, Reddy KR, Lee WM, et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized,controlled trial. Consensus Interferon Study Group. Hepatology 1997; 26(3): 747-754.
44. Tong MJ, Blatt LM, Resser KJ, et al. Treatment of chronic hepatitis C virus infection with recombinant consensus interferon. J Interferon Cytokine Res 1998; 18(2): 81-86